Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern

Augmentation of fetal hemoglobin (HbF) production has been an enduring therapeutic objective in β-thalassemia patients for which hydroxyurea (HU) has largely been the drug of choice and the most cost-effective approach. A serum metabolomics study on 40 patients with β-thalassemia prior to and after...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Ayesha, Ansari, Saqib Hussain, Parveen, Sadia, Khan, Ishtiaq Ahmad, Siddiqui, Amna Jabbar, Musharraf, Syed Ghulam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182004/
https://www.ncbi.nlm.nih.gov/pubmed/30310134
http://dx.doi.org/10.1038/s41598-018-33540-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182004/
https://www.ncbi.nlm.nih.gov/pubmed/30310134
http://dx.doi.org/10.1038/s41598-018-33540-6

Ejemplares similares